Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy
Authors:
- V. Craig JordanVJV. Craig Jordan
- 1 February 2005
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 93 (2-5) , 249-256
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Selective estrogen receptor modulationCancer Cell, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in VitroEndocrinology, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor ModulatorsJournal of Biological Chemistry, 2001
- Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancerOncogene, 2000
- Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer GrowthJNCI: Journal of the National Cancer Institute, 1998
- Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapyBreast Cancer, 1998
- A Laboratory Model To Explain the Survival Advantage Observed in Patients Taking Adjuvant Tamoxifen Therapy1993